Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/μL: A randomized trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 4, 2006, Pages 425-429

  Krolewiecki, Alejandro J ^a   Zala, Carlos ^a   Vanzulli, Claudia ^b   Pérez, Héctor ^c   Iannella, María Del Carmen ^b,d   Bouzas, María Belén ^e   Gun, Ana ^e   Valiente, José ^c   Cassetti, Isabel ^b   Cahn, Pedro ^a,c  

^a FUNDACIÓN HUÉSPED   (Argentina)

^b Helios Salud Buenos Aires ^*  (Argentina)

^c HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e Centro Medico Huésped   (Argentina)

Author keywords

CD4; HAART; HIV; Treatment interruption; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; LACTIC ACID; LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

ADULT; ARTICLE; ASTHENIA; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OPPORTUNISTIC INFECTION; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT DURATION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; LACTIC ACID; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 33646817438     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000219984.27824.6d     Document Type: Article

References (23)

1. Marins JR, Jamal LF, Chen SY, et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS. 2003;17:1675-1682.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA. 1996;276:146-154.
4. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society - USA panel. JAMA. 2000;283:381-390.
5. Yeni P, Hammer S, Carpenter C, et al. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society - USA panel. JAMA. 2002;288:222-235.
6. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. JAMA. 2004;292:251-265.
7. Dybul M, Fauci AS, Bartlett JG, et al. Panel on Clinical Practices for Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med. 2002;137:381-433.
8. + cell strata. Ann Intern Med. 2003;138:620-626.
9. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-2577.
10. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS. 2001;15:2251-2257.
11. rgentinian Health Ministry. LUSIDA. Available at: http://www.msal.gov.ar/ htm/site/Lusida/Medicamentos/CuadroOfertas.htm. Accessed June 14, 2005.
12. Pomerantz RJ. Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. HIV Clin Trials. 2003;4:137-143.
13. + T cells decline in HIV infected patients: implications for intermittent therapeutic strategies. J Infect Dis. 2002;186:851-854.
14. Tarwater PM, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis. 2003;37:1541-1548.
15. + cell count guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy. AIDS. 2004;18:2381-2389.
16. 6 cells/L. AIDS. 2005;19:53-61.
17. Perez C, Krolewiecki A, Cassetti I, et al. Strategic treatment interruption: an observational study of 145 patients in Argentina [abstract 595]. Presented at: Second IAS Conference on HIV Pathogenesis and Treatment; 2003; Paris, France.
18. Deeks S, Hirschel B. Supervised interruptions of antiretroviral therapy. AIDS. 2002;16:S157-S169.
19. Philips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug naive individuals. AIDS. 2001;15:2379-2384.
20. Ananworanich J, Nuesch R, Le Braz M, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS. 2003;17:F33-F37.
21. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074.
22. Fagard C, Oxenius A, Gunthard H, et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med. 2003;163:1220-1226.
23. Cozzi-Lepri A, Phillips AN, Miller V, et al. Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther. 2003;8:127-136.